Originally published as JCO Early Release 10.1200/JCO.2008.20.3778 on February 17 2009

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cole, P. D. Articles by Trippett, T. M. Search for Related Content PubMed PubMed Citation Articles by Cole, P. D. Articles by Trippett, T. M. Social Bookmarking                            What's this?

Phase II Study of Weekly Gemcitabine and Vinorelbine for Children With Recurrent or Refractory Hodgkin's Disease: A Children's Oncology Group Report

From the Children's Oncology Group, Arcadia, CA.

Corresponding author: Peter D. Cole, MD, Albert Einstein College of Medicine, Montefiore Medical Center, 111 East 210 St, Bronx, NY 10467; e-mail: pcole{at}aecom.yu.edu.

Purpose The Children's Oncology Group conducted this phase II study to assess the efficacy and toxicity of gemcitabine and vinorelbine (GV) in pediatric patients with heavily pretreated relapsed/refractory Hodgkin's disease. Both agents have significant single-agent response rates in this setting.

Methods GV was given on days 1 and 8 of each 21-day treatment cycle: vinorelbine 25 mg/m²/dose administered via intravenous (IV) push before gemcitabine 1,000 mg/m²/dose IV over 100 minutes. Any patients who demonstrated a measurable response (complete response [CR], very good partial response [VGPR], or partial response [PR]) were considered to have experienced a response to GV. Response was evaluated after every two cycles. A two-stage minimax rule was used to test the null hypothesis that the response rate is 40% against an alternative hypothesis of a response rate more than 65%.

Results Thirty eligible patients with a median age of 17.7 years (range, 10.7 to 29.4 years) were enrolled. All patients had received at least two prior chemotherapy regimens, and 17 patients had undergone prior autologous stem-cell transplantation. Hematologic toxicity was predominant in all treatment cycles. Nonhematologic grade 3 to 4 toxicity, including elevated hepatic enzymes and hyperbilirubinemia, was less common. Pericardial and pleural effusions developed in one patient after cycles 4 and 5 of GV, consistent with gemcitabine-induced radiation recall. There were no toxic deaths. Measurable responses were seen in 19 (76%) of 25 assessable patients (95% exact binomial CI, 55% to 91%), including six CRs, 11 VGPRs, and two PRs.

Conclusion GV is an effective and well-tolerated reinduction regimen for children with relapsed or refractory Hodgkin's disease.

Supported by National Cancer Institute Grant No. CA98543. P.D.C. is a Damon Runyon-Lilly Clinical Investigator, supported in part by the Damon Runyon Cancer Research Foundation (CI -16-03).

This study has been presented in part as a poster presentation, at the American Society of Hematology Annual Meeting, December, 2007.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Clinical Trials repository link available on JCO.org.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?